Cargando…
Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643585/ http://dx.doi.org/10.1007/s10549-014-3010-y |
| _version_ | 1782400542048256000 |
|---|---|
| author | McIntyre, Kristi O’Shaughnessy, Joyce Schwartzberg, Lee Glück, Stefan Berrak, Erhan Song, James X. Cox, David Vahdat, Linda T. |
| author_facet | McIntyre, Kristi O’Shaughnessy, Joyce Schwartzberg, Lee Glück, Stefan Berrak, Erhan Song, James X. Cox, David Vahdat, Linda T. |
| author_sort | McIntyre, Kristi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4643585 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46435852015-11-19 Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer McIntyre, Kristi O’Shaughnessy, Joyce Schwartzberg, Lee Glück, Stefan Berrak, Erhan Song, James X. Cox, David Vahdat, Linda T. Breast Cancer Res Treat Erratum Springer US 2014-06-19 2014 /pmc/articles/PMC4643585/ http://dx.doi.org/10.1007/s10549-014-3010-y Text en © Springer Science+Business Media New York 2014 |
| spellingShingle | Erratum McIntyre, Kristi O’Shaughnessy, Joyce Schwartzberg, Lee Glück, Stefan Berrak, Erhan Song, James X. Cox, David Vahdat, Linda T. Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer |
| title | Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer |
| title_full | Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer |
| title_fullStr | Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer |
| title_full_unstemmed | Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer |
| title_short | Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer |
| title_sort | erratum to: phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643585/ http://dx.doi.org/10.1007/s10549-014-3010-y |
| work_keys_str_mv | AT mcintyrekristi erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer AT oshaughnessyjoyce erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer AT schwartzberglee erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer AT gluckstefan erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer AT berrakerhan erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer AT songjamesx erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer AT coxdavid erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer AT vahdatlindat erratumtophase2studyoferibulinmesylateasfirstlinetherapyforlocallyrecurrentormetastatichumanepidermalgrowthfactorreceptor2negativebreastcancer |